PyInvesting

Market research

BALPHARMA.NSE Bal Pharma Limited

NSE INR Healthcare

Latest close

Loading market data…

Test a moving-average rule with historical data.

Market cap
1B
P/E ratio
18.81
Analyst target
Not available
Dividend yield
0.0%
Beta
0.45

Community

Investor discussion

1 comment

Admin profile picture
Admin

5 years, 5 months ago

Bal Pharma Limited is currently in a long term uptrend where the price is trading 43.1% above its 200 day moving average.

From a valuation standpoint, the stock is 91.6% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.4.

Bal Pharma Limited's total revenue rose by 46.0% to $630M since the same quarter in the previous year.

Its net income has increased by 108.5% to $3M since the same quarter in the previous year.

Finally, its free cash flow grew by 6.2% to $124M since the same quarter in the previous year.

Based on the above factors, Bal Pharma Limited gets an overall score of 5/5.